Search Results
Breast Cancer Breakthrough - Prof Andrew Tutt on the OlympiA trial
Breast Cancer Breakthrough - Professor Chris Lord on the OlympiA Trial
Prof Andrew Tutt: first targeted treatment for hereditary cancer | King's Health Partners 10 Years
OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer
ASCO 2021 - Highlights on shifting PARPi to Early Breast Cancer: The OlympiA study
Breast cancer breakthrough
Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer wit...
How Breast Cancer Now helped discover PARP inhibitors
OlympiA: adjuvant olaparib following chemo significantly improves IDFS
Dr. Stephanie Graff discusses a new, exciting breakthrough in treating breast cancer
2022 Breakthroughs & Discoveries Panel
An overview of recent metastatic HER2+ breast cancer trials
